CN112638881B - 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 - Google Patents

用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 Download PDF

Info

Publication number
CN112638881B
CN112638881B CN201980056669.3A CN201980056669A CN112638881B CN 112638881 B CN112638881 B CN 112638881B CN 201980056669 A CN201980056669 A CN 201980056669A CN 112638881 B CN112638881 B CN 112638881B
Authority
CN
China
Prior art keywords
cancer
alkyl
metastatic
halo
aldh1a3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980056669.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112638881A (zh
Inventor
马克·埃斯波西托
康毅滨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of CN112638881A publication Critical patent/CN112638881A/zh
Application granted granted Critical
Publication of CN112638881B publication Critical patent/CN112638881B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980056669.3A 2018-07-31 2019-07-31 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 Active CN112638881B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712434P 2018-07-31 2018-07-31
US62/712,434 2018-07-31
PCT/US2019/044278 WO2020028461A1 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Publications (2)

Publication Number Publication Date
CN112638881A CN112638881A (zh) 2021-04-09
CN112638881B true CN112638881B (zh) 2025-01-07

Family

ID=67734803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056669.3A Active CN112638881B (zh) 2018-07-31 2019-07-31 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物

Country Status (8)

Country Link
US (2) US12162855B2 (https=)
EP (1) EP3830079A1 (https=)
JP (1) JP7613743B2 (https=)
CN (1) CN112638881B (https=)
AU (1) AU2019315444B2 (https=)
CA (1) CA3107120A1 (https=)
IL (1) IL280395B2 (https=)
WO (1) WO2020028461A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573915A (zh) * 2014-08-01 2017-04-19 纽韦卢森公司 针对布罗莫结构域有活性的化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3701277A1 (de) 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPH01319453A (ja) * 1988-06-22 1989-12-25 Wakamoto Pharmaceut Co Ltd 新規ベンゾキノン誘導体
MXPA05012086A (es) 2003-05-12 2006-02-22 Pfizer Prod Inc Inhibidores de benzamida del receptor p2x7.
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
JP2006349902A (ja) * 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
WO2015173169A1 (en) 2014-05-12 2015-11-19 Fondazione Istituto Italiano Di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573915A (zh) * 2014-08-01 2017-04-19 纽韦卢森公司 针对布罗莫结构域有活性的化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2195663-27-3/RN;ACS;《STN Registry数据库》;1-10 *
2217474-28-5/RN;ACS;《STN Registry数据库》;1-34 *
635674-82-7/RN;ACS;《STN Registry数据库》;20150709;1-5 *

Also Published As

Publication number Publication date
AU2019315444B2 (en) 2024-10-31
IL280395B2 (en) 2025-04-01
WO2020028461A1 (en) 2020-02-06
JP7613743B2 (ja) 2025-01-15
CA3107120A1 (en) 2020-02-06
US20210155602A1 (en) 2021-05-27
EP3830079A1 (en) 2021-06-09
US12162855B2 (en) 2024-12-10
CN112638881A (zh) 2021-04-09
JP2021532158A (ja) 2021-11-25
AU2019315444A1 (en) 2021-02-11
IL280395A (en) 2021-03-01
US20250129046A1 (en) 2025-04-24
IL280395B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20250129046A1 (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
Fouassier et al. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance
CZ20014038A3 (cs) Pouľití ftalazinových derivátů
US20100093716A1 (en) Therapeutic methods using wrn binding molecules
Lallous et al. Targeting binding function-3 of the androgen receptor blocks its co-chaperone interactions, nuclear translocation, and activation
US11891399B2 (en) Inhibitors of cancer invasion, attachment, and/or metastasis
EP4531857B1 (en) Gcn2 modulator for treating advanced solid tumors or blood cancer
US20250332238A1 (en) Inhibition of histone methyl transferases to treat cancer
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
San José-Enériz et al. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Sharma et al. First-in-class dual EZH2-HSP90 inhibitor eliciting striking antiglioblastoma activity in vitro and in vivo
JP2022538767A (ja) アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
US20260007652A1 (en) Selective Modulators of AhR-Regulated Transcription and Method for Using Such Modulators to Treat Cancer
JP2022526844A (ja) 筋肉量及び酸化的代謝を増加させるための組成物及び方法
KR101655697B1 (ko) 신규한 피라졸린 유도체 및 이의 용도
HK40049062A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
US20210009551A1 (en) Compounds and methods for treating fibrosis or cancer
HK40049062B (zh) 用於治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
US12570661B2 (en) Isoform-specific aldehyde dehydrogenase inhibitors
JP2024509887A (ja) Ｅｐ３００分解剤および神経芽細胞腫におけるその使用
Zhang et al. Nicotinic acid suppresses liver cancer metastasis via histone lysine nicotinylation
WO2025137355A1 (en) Proxy binding for screening therapeutic compounds
Reed Mechanisms of DNA Damage Tolerance in Glioblastoma
JP2025521593A (ja) ３βＨＳＤ１阻害剤及び組成物ならびにそれらの使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049062

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant